NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
- Corax Consultants LLC
- 11. Apr. 2024
- 1 Min. Lesezeit
The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation. NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
Kommentare